Cargando…

The Role of New Technologies in Myeloproliferative Neoplasms

The hallmark of BCR-ABL1-negative myeloproliferative neoplasms (MPNs) is the presence of a driver mutation in JAK2, CALR, or MPL gene. These genetic alterations represent a key feature, useful for diagnostic, prognostic and therapeutical approaches. Molecular biology tests are now widely available w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palumbo, Giuseppe A., Stella, Stefania, Pennisi, Maria Stella, Pirosa, Cristina, Fermo, Elisa, Fabris, Sonia, Cattaneo, Daniele, Iurlo, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498877/ https://www.ncbi.nlm.nih.gov/pubmed/31106152 http://dx.doi.org/10.3389/fonc.2019.00321

Ejemplares similares

Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review
por: Barozzi, Enrico, et al.
Publicado: (2022)

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
por: Iurlo, Alessandra, et al.
Publicado: (2019)

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
por: Cattaneo, Daniele, et al.
Publicado: (2021)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study
por: Cattaneo, Daniele, et al.
Publicado: (2021)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
por: Hermouet, Sylvie
Publicado: (2023)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms
por: Lim, Ken-Hong, et al.
Publicado: (2021)

The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
por: Pettersson, Helna, et al.
Publicado: (2023)

Myeloproliferative neoplasms – blurring the lines between cancer and chronic inflammatory disorder
por: Soyfer, Eli M., et al.
Publicado: (2023)

Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
por: Cominal, Juçara Gastaldi, et al.
Publicado: (2021)

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
por: Pasquale, Raffaella, et al.
Publicado: (2022)

Tracking fibrosis in myeloproliferative neoplasms by CCR2 expression on CD34(+) cells
por: Pozzi, Giulia, et al.
Publicado: (2022)

Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases
por: La Spina, Enrico, et al.
Publicado: (2023)

Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study
por: Bucelli, Cristina, et al.
Publicado: (2021)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
por: Barbui, Tiziano, et al.
Publicado: (2021)

Paroxysmal Nocturnal Hemoglobinuria in the Context of a Myeloproliferative Neoplasm: A Case Report and Review of the Literature
por: Giannotta, Juri Alessandro, et al.
Publicado: (2021)

Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review
por: Malato, Alessandra, et al.
Publicado: (2020)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms
por: Moia, Riccardo, et al.
Publicado: (2021)

Case Report: Concomitant Diagnosis of Plasma Cell Leukemia in Patient With JAK2 Positive Myeloproliferative Neoplasm
por: Kurian, Christine J., et al.
Publicado: (2020)

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review
por: Sun, Yingxin, et al.
Publicado: (2021)

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
por: Tirrò, Elena, et al.
Publicado: (2019)

CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016)

Treatment of Myelofibrosis: Old and New Strategies
por: Iurlo, Alessandra, et al.
Publicado: (2017)

Acute myocardial infarction in myeloproliferative neoplasms
por: Manan, Muhammad Romail, et al.
Publicado: (2023)

The Role of Inflammation and Inflammasome in Myeloproliferative Disease
por: Longhitano, Lucia, et al.
Publicado: (2020)

The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy
por: Vigneri, Paolo Giovanni, et al.
Publicado: (2015)

Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms
por: Vanni, Daniele, et al.
Publicado: (2022)

AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells
por: Pearson, Stella, et al.
Publicado: (2019)

The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms
por: Lanzarone, Giuseppe, et al.
Publicado: (2021)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8hl91jeeiacardvjs7n0r4s1vm